We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
Our PCA approach may represent a transformative step in the evolution of regenerative medicine, reducing complexity by temporarily reactivating progenitor cells already located at the tissue target site – and pre-programmed to make specific cell types.
Naturally repairing or reversing damage caused by degenerative disease
Harvard Medical School; Massachusetts Eye & Ear Infirmary
University of Wisconsin
Vanderbilt University
Massachusetts Eye & Ear Infirmary
St. Joseph Hospital
